Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


MAT Biopharma to enter in a research collaboration with AlgoNomics

Evry, France and Ghent, Belgium - June 12, 2006 - MAT Biopharma SA and AlgoNomics NV today announced they entered into a research collaboration. AlgoNomics will employ its structural bioinformatics platform to assist MAT Biopharma in its research related to the structural analysis of its antibody leads. The research collaboration focused on increasing the structural insight and potential immunogenicity of antibodies against hematological cancer and some solid cancers. Financial terms of the collaboration and the therapeutic focus of the collaboration were not disclosed.

“We are impressed by AlgoNomics’ Epibase® and structural bioinformatics platforms. We expect that this will add significant value to our lead discovery and development programs”, stated Dr. Jean Kadouche, CEO of MAT Biopharma.

Dr. Ignace Lasters, CEO of AlgoNomics, comments: “We are pleased to be working with MAT Biopharma. Adding a structural perspective to the outstanding biological and clinical insights of their scientific team is likely not only to strengthen the intellectual property position of MAT Biopharma but also to accelerate the drug development process”.

About MAT Biopharma SA

MAT Biopharma is a biopharmaceutical company created in December 1999 at the Genopole Evry, near Paris (France). The company develops antibody-based therapeutics for the treatment of Hodgkin’s disease, acute myeloid leukaemia, chronic lymphocytic leukaemia and some solid cancers. Additionally, MAT offers high-throughput screening services for antibodies to pharmaceutical and biotech companies. For more information about MAT Biopharma visit

About AlgoNomics

AlgoNomics is a Belgium based biotech company providing structural bioinformatics services to develop rationally designed therapeutics in the broad field of immunotherapy. AlgoNomics owns a rich, proprietary platform for structure-based protein and peptide design. The technology platform contains innovative tools to unravel protein-protein and protein-peptide interactions.

AlgoNomics’ premier product is the Epibase® platform for T-cell epitope identification in different population groups, applied in the discovery of vaccines and therapeutic proteins. For more information about AlgoNomics visit

Further Information
AlgoNomics N.V.
ir. Philippe Stas
Chief Operating Officer
Technologiepark 4
B-9052 Gent – Belgium
Tel.: +32.(0)
Fax.: +32.(0)

Epibase® and Immunotuning® are trademarks of AlgoNomics NV.

MAT Biopharma
Dr. Franziska Possmayer
Director Business Development
4 rue Pierre Fontaine
F-91058 Evry Cedex, France
Tel.: +33 (0)1 60 87 89 26
Fax: +33 (0)1 60 87 89 64

Publisher Contact Information:


Company profile of AlgoNomics (acquired by Lonza Group)
Past press releases of AlgoNomics (acquired by Lonza Group).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Oct 19€3.0MInternet services
Oct 19€6.0MBusiness applications
Oct 18€11.0MConsumer electronics
Oct 18€5.0MBusiness applications
Oct 17€5.9MBiopharmaceuticals
Oct 16€3.7MContent management
Oct 16€7.8MSensors

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.